Company profilePharmaceutical#37 of 1,318 in Pakistan✓ No DRAP alerts

M/s. Genix Pharma (Pvt) Ltd.

Pharmaceutical company · 276 brands · 207 molecules

Ranked #18 of 62 companies in Antivirals For Systemic Use

276 registered products 70 pharmaceutical brands 207 distinct molecules 0 DRAP alerts

Company overview

276
registered products
70
pharmaceutical brands
207
distinct molecules
8
therapeutic classes
0
DRAP alerts

M/s. Genix Pharma (Pvt) Ltd. is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 276 product registrations across 207 distinct molecules. It is the 37th largest registrant in Pakistan by product count, and ranks 18th of 62 in Antivirals For Systemic Use. Its portfolio is concentrated in Antivirals For Systemic Use and Antiepileptics. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by M/s.

59 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

58
ceilings with an approval date
0
not revised in 2+ years
2025
oldest approval year
20251
202657

Top molecules by brand count

Therapeutic classes

Antivirals For Systemic Use · 4Antiepileptics · 1Other Beta-Lactam, Cephalosporins & Penems · 1Angiotensin-Ii Antagonists, Combinations · 1Quinolone Antibacterials · 1Drugs For Obstructive Airway Diseases, Inhalants · 1Macrolides, Lincosamides And Streptogramins · 1Antihaemorrhagic · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official334 products · Rs 4.48 – Rs 130,361.67
DVAGO4 products · Rs 206.15 – Rs 2,013.38
Median across source: Rs 592.02

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

HILTON PHARMA (PVT) LIMITED holds 144 molecules not in this portfolio
15 Microgram Of Each Strain H1AlprazolamAlum Hydroxide GelAmlodipineAmodiaquineApixaban
GETZ PHARMA PAKISTAN (PVT) LTD. holds 258 molecules not in this portfolio
),Formoterol3 ) 20Mg} Folic AcidAcetazolamideAcyclovirAdrenalineAlbendazole
GENOME PHARMACEUTICALS (PVT) LTD holds 103 molecules not in this portfolio
AcitretinAmlodipineAnastrazoleAnastrozoleAprepitantArtesunate

Get the full profile for M/s.

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.